Company news
Senti Biosciences Holdings, Inc. (NASDAQ:SNTI) news
Senti Biosciences Holdings, Inc. news releases on 6ix. Latest, Jan 6, 2025: Senti Bio Announces Additional $11.5 Million of Financing
Press releases — page 2
Senti Bio Announces Additional $11.5 Million of Financing
January 5, 2025
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
December 15, 2024
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
December 1, 2024
Senti Bio Appoints Fran Schulz to Board of Directors
December 1, 2024
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML
December 1, 2024
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
November 13, 2024
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
August 12, 2024
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
August 4, 2024
Senti Bio Announces Reverse Stock Split
July 15, 2024
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
June 30, 2024
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
May 12, 2024
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
May 8, 2024
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
April 29, 2024
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
March 20, 2024
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
January 4, 2024
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
December 21, 2023
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
November 12, 2023
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
November 5, 2023
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
October 30, 2023
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
September 26, 2023
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
August 10, 2023
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
August 9, 2023
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
May 8, 2023
Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
May 1, 2023
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
March 21, 2023
Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
March 13, 2023
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
January 26, 2023
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
December 10, 2022
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
November 9, 2022
Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting
November 2, 2022
Senti Bio Announces New Employment Inducement Grants
October 27, 2022
Senti Bio Reports Second Quarter Financial Results and Business Updates
August 14, 2022
Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits
June 8, 2022
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies
December 19, 2021